Thu, March 14, 2024
Wed, March 13, 2024
Tue, March 12, 2024
Mon, March 11, 2024
Fri, March 8, 2024

Joel Beatty Maintained (ACAD) at Buy with Decreased Target to $31 on, Mar 12th, 2024


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-31-on-mar-12th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Joel Beatty of Baird, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $40 to $31 on, Mar 12th, 2024.

Joel has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 2 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $27 on, Monday, December 18th, 2023
  • Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023


These are the ratings of the 3 analyists that currently disagree with Joel


  • Tessa Romero of "JP Morgan" Maintained at Buy with Decreased Target to $29 on, Friday, March 1st, 2024
  • Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
  • Jeffrey Hung of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $40 on, Tuesday, December 19th, 2023

Publication Contributing Sources